(Updates with closing share price in second paragraph.)
Oct. 5 (Bloomberg) -- BTG Plc, a British specialist drugmaker, rose the most in more than a year in London trading after saying 2012 sales may beat analyst estimates, helped by new treatments and a rival’s product withdrawal.
BTG jumped 27 pence, or 11 percent, to 265 pence, the biggest gain since Sept. 10, 2010.
Sales for the 12 months through March 2012 may total as much as 165 million pounds ($255 million), London-based BTG said today in a statement. That compares with the 140 million-pound average of 11 analyst estimates compiled by Bloomberg.
Revenue has been boosted by regulatory approval for Zytiga, a hormone therapy for prostate cancer, as well as demand for its hemophilia drug Benefix, BTG said. Sales of the company’s DigiFab digoxin-poisoning antidote, approved for marketing in the U.K. in July, have been helped by GlaxoSmithKline Plc’s withdrawal of the competing DigiBind treatment, it said.
--Editors: Tom Lavell, David Risser
To contact the reporter on this story: Makiko Kitamura in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com